NTRA vs WGS
NTRA: Natera is a pioneer in cell-free DNA testing, providing advanced genetic insights across prenatal, oncology, and organ health applications. WGS: GeneDx uses AI-powered genomics to provide precise, actionable clinical genetic testing for rare and complex diseases.
Side-by-side fundamentals
| Metric | NTRA | WGS | Edge |
|---|---|---|---|
| Price as of 2026-08-21 close | $332.03 | $87.07 | |
| Market cap as of 2026-08-24 | $47.9B | $2.6B | |
| PEG as of 2026-08-24 | n/a | -0.30 | |
| Net margin as of 2026-08-24 | -7.1% | -23.4% | NTRA higher |
| Gross margin as of 2026-08-24 | +65.2% | +69.4% | WGS higher |
| Operating margin as of 2026-08-24 | -10.7% | -21.8% | NTRA higher |
| ROE as of 2026-08-24 | -11.7% | -38.7% | NTRA higher |
| ROA as of 2026-08-24 | -8.1% | -21.2% | NTRA higher |
| Debt / equity as of 2026-08-24 | 0.04 | 0.40 | NTRA lower |
| Revenue growth (YoY) as of 2026-08-24 | +37.8% | +25.4% | NTRA higher |
| Revenue CAGR (3y) SEC XBRL | +41.1% | +22.1% | NTRA higher |
| Beta as of 2026-08-24 | 1.56 | 1.98 | |
| 1-year return as of 2026-08-21 close | +105.0% | -27.9% | NTRA higher |
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.